DKA Resolution Criteria
DKA is considered resolved when ALL three criteria are met: glucose <200 mg/dL, serum bicarbonate ≥18 mEq/L, and venous pH ≥7.3 1.
The Three Required Parameters
The established guideline criteria require simultaneous achievement of:
- Glucose <200 mg/dL
- Serum bicarbonate ≥18 mEq/L
- Venous pH ≥7.3
All three must be present before transitioning from intravenous to subcutaneous insulin 1.
Monitoring Strategy
What to Check and When
- Draw blood every 2-4 hours during DKA treatment for electrolytes, glucose, BUN, creatinine, osmolality, and venous pH 1
- Use venous pH, not arterial blood gases - repeat arterial sampling is unnecessary as venous pH and anion gap adequately monitor acidosis resolution 1
- Venous pH is typically ~0.03 units lower than arterial pH 1
Important Monitoring Pitfall
Do not use nitroprusside-based ketone measurements (urine or serum) to assess treatment response. This method only detects acetoacetate and acetone, missing β-hydroxybutyrate (β-OHB), which is the predominant ketoacid in DKA. During treatment, β-OHB converts to acetoacetate, falsely suggesting worsening ketosis when the patient is actually improving 1.
If measuring ketones directly, β-OHB blood measurement is preferred for monitoring 1.
Alternative Parameters: Emerging Evidence
Anion Gap as Earlier Marker
Recent research suggests anion gap ≤12 mmol/L may identify resolution approximately 5-6 hours faster than traditional pH and bicarbonate criteria 2. In one pediatric study, 75% of patients reached AG ≤12 mmol/L before meeting the standard pH/bicarbonate thresholds, with median time to AG normalization of 12 hours versus 17-18 hours for pH and bicarbonate 2.
β-Hydroxybutyrate Considerations
While newer guidelines suggest β-OHB monitoring, using β-OHB <1.5 mmol/L as a resolution criterion actually delays transition to subcutaneous insulin compared to anion gap monitoring (median 23.5 hours vs 13.3 hours), with no difference in DKA recurrence rates 3. A β-OHB threshold of <1.5 mmol/L shows 83% sensitivity and 87% specificity for DKA resolution when compared to AG ≤14 mmol/L 4.
Clinical Algorithm
Follow the established guideline criteria 1:
Continue IV insulin until ALL three parameters are met:
- Glucose <200 mg/dL
- Bicarbonate ≥18 mEq/L
- Venous pH ≥7.3
Once resolved, if patient is NPO: continue IV insulin and supplement with subcutaneous regular insulin every 4 hours as needed
When patient can eat: initiate multi-dose subcutaneous insulin regimen
Critical transition step: Continue IV insulin for 1-2 hours after starting subcutaneous insulin to ensure adequate plasma insulin levels and prevent rebound hyperglycemia 1
Key Pitfall to Avoid
Abrupt discontinuation of IV insulin when starting subcutaneous insulin leads to poor glycemic control and potential DKA recurrence. Always overlap the two regimens by 1-2 hours 1.